KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinomaNikolaj Frost, Christian Grohé, Burkhard Matthes et al.|Translational Lung Cancer Research|2021Cited by 60
Pembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer populationN. Frost, Christian Grohé, Jens Kollmeier et al.|Annals of Oncology|2019Cited by 3